BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 33131448)

  • 1. Dermatological side effects of immunotherapy drugs and targeted cancer therapies: Importance of dermatology and oncology collaboration.
    Çelik U; Aydemir EH; Engin B; Oba MÇ; Yılmaz M; Meşe ŞG
    J Oncol Pharm Pract; 2021 Dec; 27(8):1853-1860. PubMed ID: 33131448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.
    Lacouture M; Sibaud V
    Am J Clin Dermatol; 2018 Nov; 19(Suppl 1):31-39. PubMed ID: 30374901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.
    Grávalos C; Sanmartín O; Gúrpide A; España A; Majem M; Suh Oh HJ; Aragón I; Segura S; Beato C; Botella R
    Clin Transl Oncol; 2019 May; 21(5):556-571. PubMed ID: 30284232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dermatological side effects of targeted antineoplastic therapies: a prospective study.
    Agirgol S; Çaytemel C; Pilanci KN
    Cutan Ocul Toxicol; 2020 Dec; 39(4):380-384. PubMed ID: 33028137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study.
    Barrios DM; Phillips GS; Freites-Martinez A; Hsu M; Ciccolini K; Skripnik Lucas A; Marchetti MA; Rossi AM; Lee EH; Deng L; Markova A; Myskowski PL; Lacouture ME
    J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1340-1347. PubMed ID: 31856311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous Complications of Targeted Melanoma Therapy.
    de Golian E; Kwong BY; Swetter SM; Pugliese SB
    Curr Treat Options Oncol; 2016 Nov; 17(11):57. PubMed ID: 27645330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
    Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
    Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
    Yalici-Armagan B; Ayanoglu BT; Demirdag HG
    Cutan Ocul Toxicol; 2019 Sep; 38(3):261-266. PubMed ID: 31010330
    [No Abstract]   [Full Text] [Related]  

  • 9. Skin rash associated with combined cytotoxic chemotherapy and immunotherapy for cancer: A retrospective single-center case series.
    Yahiro C; Takai T; Nakatani S; Tanaka N; Goto A
    J Dermatol; 2023 Mar; 50(3):357-363. PubMed ID: 36258256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
    Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
    Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing Cutaneous Side Effects From Targeted Molecular Inhibitors for Melanoma and Nonmelanoma Skin Cancer.
    Tang N; Ratner D
    Dermatol Surg; 2016 Jan; 42 Suppl 1():S40-8. PubMed ID: 26730973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic.
    Rosen AC; Case EC; Dusza SW; Balagula Y; Gordon J; West DP; Lacouture ME
    Am J Clin Dermatol; 2013 Aug; 14(4):327-33. PubMed ID: 23625802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
    Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
    Plachouri KM; Vryzaki E; Georgiou S
    Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies.
    Plachouri KM; Florou V; Georgiou V; Georgiou S
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Skin changes as a result of targeted therapies in oncology patients: cutaneous side effects of targeted therapies in oncology patients].
    Kähler KC; Hauschild A
    Hautarzt; 2009 May; 60(5):433-40. PubMed ID: 19430753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Side effects of systemic oncological therapies in dermatology.
    Zimmer L; Vaubel J; Livingstone E; Schadendorf D
    J Dtsch Dermatol Ges; 2012 Jul; 10(7):475-86. PubMed ID: 22571234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
    Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
    JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using a cancer registry to capture signals of adverse events following immune and targeted therapy for melanoma.
    Aguiar JP; Cardoso Borges F; Murteira R; Ramos C; Gouveia E; Passos MJ; Miranda A; da Costa FA
    Int J Clin Pharm; 2018 Aug; 40(4):852-861. PubMed ID: 29860707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
    Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
    J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.